Summary: Hospitalized patients with severe COVID-19 who received remdesivir recovered 31% faster than those who received placebo (median time to recovery was 11 days vs. 15 days), according to an interim analysis from a randomized, controlled trial of 1,063 patients. Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), this is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19. There was also a statistically non-significant survival benefit, with a mortality rate of 8.0% in patients receiving remdesivir vs. a mortality rate of 11.6% in patients receiving placebo (p=0.059).
Information current as of 04/29/2020
Organization: National Institutes of Health (NIH)
Title: NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19
Web Link: Read more here!